NWBioTrust (NWBT) is a new established resource that represents the maturation of the Developing Tissue Bank Shared Resource currently funded by the Cancer Center Support Grant (CCSG). The CCSG, as well as two major grants totaling $6.75M from Washington State's Life Sciences Discovery Fund (LSDF), funded much of the early developmental work of NWBT. NWBT is the result of a successful collaboration between the UW departments of Pathology, Laboratory Medicine, and Biomedical Informatics and Medical Education (BIME), the UW Institute of Translational Health Sciences (local CTSA), FHCRC, SCCA and Children's. The mission of NWBT is to provide reliable and cost-effective access to high-quality human tissue, blood and other body fluid samples, and associated clinical and specimen annotation data, for innovative diagnostic, therapeutic and public health sciences cancer research. The resource provides the following services: ? Prospective collection of annotated research-only tissue, blood, and other specimens; ? High-throughput collections of annotated remnant diagnostic materials; and ? Identification of existing annotated repository samples using a Virtual Biospecimen Discovery (VBD) system. NWBT provides an important role to ensure that the well established Consortium cancer repositories acquire and maintain sufficient biospecimens to support a wide range of research studies. NWBT also staffs a fee-for- service office whereby researchers may extract EMR-derived data which may be linked to specimens (either identified, or de-identified via NWBT sample codes, depending on IRB permissions).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-40
Application #
8804785
Study Section
Subcommittee G - Education (NCI)
Project Start
2015-02-01
Project End
2019-12-31
Budget Start
2015-02-01
Budget End
2015-12-31
Support Year
40
Fiscal Year
2015
Total Cost
$393,698
Indirect Cost
$155,493
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mora-Pinzon, Maria C; Trentham-Dietz, Amy; Gangnon, Ronald E et al. (2018) Urinary Magnesium and Other Elements in Relation to Mammographic Breast Density, a Measure of Breast Cancer Risk. Nutr Cancer 70:441-446
Shirts, Brian H; Konnick, Eric Q; Upham, Sarah et al. (2018) Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 103:19-29
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Suzuki, Aussie; Gupta, Amitabha; Long, Sarah K et al. (2018) A Kinesin-5, Cin8, Recruits Protein Phosphatase 1 to Kinetochores and Regulates Chromosome Segregation. Curr Biol 28:2697-2704.e3
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis. J Cell Sci 131:
Kuzma, Jessica N; Hagman, Derek K; Cromer, Gail et al. (2018) Intra-individual variation in markers of intestinal permeability and adipose tissue inflammation in healthy normal weight to obese adults. Cancer Epidemiol Biomarkers Prev :
Adrianse, Robin L; Smith, Kaleb; Gatbonton-Schwager, Tonibelle et al. (2018) Perturbed maintenance of transcriptional repression on the inactive X-chromosome in the mouse brain after Xist deletion. Epigenetics Chromatin 11:50
Walter, Roland B; Othus, Megan; Orlowski, Kaysey F et al. (2018) Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica 103:e106-e109
Thornblade, Lucas W; Mulligan, Michael S; Odem-Davis, Katherine et al. (2018) Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer. Ann Thorac Surg 106:1460-1467
Poston, Jacqueline N; Fromm, Jonathan R; Rasmussen, Heather A et al. (2018) A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. Br J Haematol :

Showing the most recent 10 out of 1267 publications